Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
DynaCird
Synonyms :
isradipine
Class :
Calcium channel blockers and antihypertensives
Dosage Forms & StrengthsÂ
Capsule, Oral:Â
2.5 mfÂ
5 mgÂ
2.5
mg
capsule
Oral
twice a day
at the interval of 2 to 4 weeks
No safe and efficacious dose describedÂ
Refer to adult dosingÂ
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect
may increase the QTc prolonging effect
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may increase the QTc prolonging effect of QT-prolonging agents
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with delamanid
dasatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
encorafenib: they may increase the QTc-prolonging effect of QTc-prolonging agents
etelcalcetide: they may increase the QTc-prolonging effect of QTc-prolonging agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fluconazole: they may increase the QTc-prolonging effect of QTc-prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
sunitinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
dapagliflozin: it may increase the risk or severity of QTc prolongation
CYP3A strong enhancers of the small intestine may reduce the bioavailability of isradipine
it may enhance the QTc-prolonging effect of terfenadine
may have an increased hyperkalemic effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
bunazosin (Not available in the United States)
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with pazopanib
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
levoketoconazole: they may increase the QTc-prolonging effect of QTc-prolonging Agents
probucol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
the QTc-prolonging effect of citalopram can be increased with QT-prolonging agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance toxicity when combined with cholic acid by diminishing the elimination
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
isradipine: they may enhance the serum concentration of CYP3A4 inhibitors
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
reduction in bloop pressure is seen with carnosine when used in combination
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
the effect of isradipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
It enhances the anti-hypertensive channel blocking when combined
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increasingly adverse effect when combined with atosiban
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
fingolimod: they may increase the QTc-prolonging effect of QT-prolonging Agents
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
the : QTc-prolonging effect of hydroxyzine can be increased with QT-prolonging agents
cetirizine: it may increase the risk or severity of QTc prolongation
atropine: it may increase the risk or severity of QTc prolongation
benorilate: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
canagliflozin: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
lapatinib increases the effect of isradipine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may increase the level of each other by unknown mechanism
QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of domperidone
Frequency defined:Â Â Â
>10%Â
Headache  Â
1% to 10%Â
VomitingÂ
HeadacheÂ
Kidney injury Â
EdemaÂ
FatigueÂ
Skin rash Â
<1% PostmarketingÂ
Myocardial infarctionÂ
SyncopeÂ
DyspneaÂ
Pregnancy consideration: isradipine may cross the umbilical cord and may show some adverse effects on the unborn child.Â
Lactation: excretion of isradipine in breast milk is not known. Â
Pregnancy category:Â
Â
Patient information leafletÂ
Generic Name: IsradipineÂ
Pronounced: isradipine Â
Why do we use isradipine?Â
Isradipine is used for the treatment of hypertension and may be prescribed for other reasons by a doctor.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
